NEWRON PHARMACEUT. EO-20 (NP5) — Strategic Asset Allocation Index
NEWRON PHARMACEUT. EO-20 (NP5) has a Strategic Asset Allocation Index of 18.6% as of December 2021. Strategic assets (PP&E of €577.00K plus long-term investments of €-) total €577.00K, measured against net assets of €3.11 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See NEWRON PHARMACEUT. EO-20 (NP5) balance sheet quality index to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
NEWRON PHARMACEUT. EO-20 Strategic Asset Allocation Index (2016–2021)
This chart shows how NEWRON PHARMACEUT. EO-20's Strategic Asset Allocation Index has evolved across 6 annual periods from 2016 to 2021. As of December 2021, the index stands at 18.6%, representing strategic assets of €577.00K against net assets of €3.11 Million EUR. For live market cap and overall valuation, see NP5 company net worth.
Annual Strategic Asset Allocation Index for NEWRON PHARMACEUT. EO-20 (2016–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for NEWRON PHARMACEUT. EO-20 from 2016 to 2021, covering 6 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See NEWRON PHARMACEUT. EO-20 (NP5) shareholders funds for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (EUR) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 18.6% | €577.00K | €577.00K | €- | €3.11 Million | ▲ +14.3 pp |
| 2020 | 4.3% | €734.00K | €734.00K | €- | €17.25 Million | ▲ +3.6 pp |
| 2019 | 0.7% | €252.00K | €252.00K | €- | €36.80 Million | ▲ +0.0 pp |
| 2018 | 0.7% | €374.00K | €374.00K | €- | €54.84 Million | ▲ +0.5 pp |
| 2017 | 0.2% | €107.00K | €107.00K | €- | €67.72 Million | ▼ -0.1 pp |
| 2016 | 0.2% | €120.00K | €120.00K | €- | €49.75 Million | — |